Payment overview · 2025
General Payments
$201.72
11 reported records · 5 companies
Healthcare provider profile · identity verified
David J Gooding, DO
Allopathic & Osteopathic Physicians|Family Medicine · ENGLEWOOD, FL · NPI 1053377010
Verified facts
What the public records show
CMS Open Payments records show David J Gooding, DO received $201.72 in general payments during 2025 across 11 reported records.
Amgen Inc. accounted for 49.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $99.30 | 49.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.94 | 16.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.91 | 14.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.64 | 10.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.93 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $201.72 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.42 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.49 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1544 | 456 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1002 | 329 |
| Amlodipine Besylate | Amlodipine Besylate | 805 | 241 |
| Levothyroxine Sodium | Levothyroxine Sodium | 752 | 213 |
| Lisinopril | Lisinopril | 618 | 186 |
| Losartan Potassium | Losartan Potassium | 597 | 182 |
| Metoprolol Succinate | Metoprolol Succinate | 463 | 145 |
| Omeprazole | Omeprazole | 416 | 127 |
| Pravastatin Sodium | Pravastatin Sodium | 389 | 130 |
| Allopurinol | Allopurinol | 385 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 377 | 134 |
| Sertraline Hcl | Sertraline Hcl | 307 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 286 | 96 |
| Metformin Hcl | Metformin Hcl | 257 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 77 |
| Alendronate Sodium | Alendronate Sodium | 249 | 91 |
| Metformin Hcl Er | Metformin Hcl | 244 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 226 | 65 |
| Gabapentin | Gabapentin | 224 | 73 |
| Potassium Chloride | Potassium Chloride | 210 | 67 |
| Fluticasone Propionate | Fluticasone Propionate | 196 | 81 |
| Eliquis | Apixaban | 192 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 181 | 64 |
| Ezetimibe | Ezetimibe | 181 | 63 |
| Trazodone Hcl | Trazodone Hcl | 181 | 51 |
| Famotidine | Famotidine | 174 | 53 |
| Prednisone | Prednisone | 167 | 118 |
| Simvastatin | Simvastatin | 167 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 47 |
| Azithromycin | Azithromycin | 130 | 114 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 127 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 121 | 36 |
| Tramadol Hcl | Tramadol Hcl | 119 | 33 |
| Furosemide | Furosemide | 116 | 45 |
| Alprazolam | Alprazolam | 114 | 37 |
| Montelukast Sodium | Montelukast Sodium | 114 | 36 |
| Atenolol | Atenolol | 106 | 30 |
| Finasteride | Finasteride | 100 | 32 |
| Spironolactone | Spironolactone | 97 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 32 |
| Fenofibrate | Fenofibrate | 96 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 91 | 78 |
| Carvedilol | Carvedilol | 91 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 27 |
| Donepezil Hcl | Donepezil Hcl | 88 | 25 |
| Jardiance | Empagliflozin | 87 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 29 |
| Bumetanide | Bumetanide | 85 | 27 |
| Glimepiride | Glimepiride | 79 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 20 |
| Lorazepam | Lorazepam | 77 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 24 |
| Clonazepam | Clonazepam | 68 | 22 |
| Valsartan | Valsartan | 68 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 67 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 18 |
| Synthroid | Levothyroxine Sodium | 63 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 62 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 62 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 39 |
| Bupropion Xl | Bupropion Hcl | 55 | 23 |
| Ramipril | Ramipril | 53 | 16 |
| Warfarin Sodium | Warfarin Sodium | 52 | 13 |
| Chlorthalidone | Chlorthalidone | 50 | 16 |
| Benazepril Hcl | Benazepril Hcl | 49 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 44 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 44 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 48 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 16 |
| Memantine Hcl | Memantine Hcl | 47 | 11 |
| Estradiol | Estradiol | 46 | 19 |
| Amoxicillin | Amoxicillin | 44 | 40 |
| Irbesartan | Irbesartan | 44 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 44 | 14 |
| Acyclovir | Acyclovir | 43 | 17 |
| Farxiga | Dapagliflozin Propanediol | 43 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 13 |
| Meloxicam | Meloxicam | 42 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 35 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 41 |
| Lovastatin | Lovastatin | 39 | 14 |
| Temazepam | Temazepam | 39 | 11 |
| Celecoxib | Celecoxib | 36 | 15 |
| Ozempic | Semaglutide | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 16 |
| Aripiprazole | Aripiprazole | 34 | 13 |
| Valacyclovir | Valacyclovir Hcl | 34 | 17 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 34 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | 18 |
| Digoxin | Digoxin | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 28 | 13 |
| Cephalexin | Cephalexin | 27 | 24 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 14 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 19 |
| Fluconazole | Fluconazole | 24 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 15 |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 13 |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 11 |
| Diazepam | Diazepam | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $201.72 · 11 records | Amgen Inc. | AIRSUPRA, EVENITY, OTEZLA, Ozempic, QULIPTA, REPATHA, UBRELVY, WATCHMAN FLX | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error